[Federal Register Volume 83, Number 152 (Tuesday, August 7, 2018)]
[Notices]
[Page 38707]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16839]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by emailing the indicated licensing contact at the National Heart,
Lung, and Blood, Office of Technology Transfer and Development Office
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda,
MD 20892-2479; telephone: 301-402-5579. A signed Confidential
Disclosure Agreement may be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve commercialization of results of
federally-funded research and development.
Technology description follows.
Neuroendocrine Tumor Evans Blue Containing Radiotherapeutics
The invention pertains to a radiotherapeutic against neuroendocrine
tumors that express somatostatin receptor. Radionuclide therapies
directed against tumors that express somatostatin receptors (SSTRs)
have proven effective for the treatment of advanced, low- to
intermediate-grade neuroendocrine tumors. The subject radiotherapeutic
covered by the subject patent estate includes a somatostatin (SST)
peptide derivative like octreotate (TATE), conjugated to an Evans Blue
(EB) analog, and further chelated via DOTA to therapeutic
radionuclide\177\Lu, a beta emitter. The EB analog reversibly binds to
circulating serum albumin and improves the pharmacokinetics of SST
peptide derivatives and reduce peptide-receptor radionuclide therapy
toxicity. EB analog conjugated to octreotate (EB-DOTATATE) has been
shown by the inventors to provide reversible albumin binding in vivo
and extended half-life in circulation. When EB-TATE is slowly released
into the tumor microenvironment, tumor uptake and internalization into
SSTR positive tumors resulted in delivery of radioactive particles and
tumor cell killing. EB-TATE displayed significantly more favorable
pharmacokinetics than TATE alone by achieving higher tumor to non-tumor
penetration as evidenced by positron emission tomography.
Potential Commercial Applications:
Cancer therapeutics
Higher stability/Lower toxicity
Development Stage:
Early stage
Inventors: Xiaoyuan Chen and Orit Jacobson Weiss (both of NIBIB).
Intellectual Property: HHS Reference No. E-150-2016-1;
International Patent Application PCT/US2017/031696.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
[email protected].
Dated: July 20, 2018.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-16839 Filed 8-6-18; 8:45 am]
BILLING CODE 4140-01-P